Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 1:29 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 133 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Migraine
Interventions
Galcanezumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
13
States / cities
Santa Monica, California • Spring Valley, California • Stamford, Connecticut + 10 more
Conditions
Chronic Migraine
Interventions
Botulinum toxin type A, Placebo
Biological · Other
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
759 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
72
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 61 more
Completed Phase 4 Interventional Results available

Drug and Non-Drug Treatment Of Severe Migraine

NCT00910689
Conditions
Migraine Headache
Interventions
Propranolol or nadolol, Placebo control, Behavioral Migraine Management (BMM), Optimal Acute Therapy
Drug · Behavioral
Lead sponsor
Ohio University
Other
Eligibility
18 Years to 65 Years
Enrollment
232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
2
States / cities
Athens, Ohio • Westerville, Ohio
Conditions
Migraine, Medication Overuse Headache
Interventions
Eptinezumab, Placebo
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
608 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
6
States / cities
Winter Haven, Florida • Marrero, Louisiana • Springfield, Missouri + 3 more
Conditions
Migraine
Interventions
Ubrogepant, Placebo for Ubrogepant
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older · Female only
Enrollment
496 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
103
States / cities
Birmingham, Alabama • Huntsville, Alabama • Chandler, Arizona + 92 more
Conditions
Chronic Migraine
Interventions
Atogepant 30 mg, Atogepant 60 mg, Placebo
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 80 Years
Enrollment
778 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
41
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Fresno, California + 35 more
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Pilot Study to Compare Frovatriptan vs. Topiramate for Prevention of Migraine

NCT00846495
Conditions
Migraine
Interventions
topiramate, frovatriptan
Drug
Lead sponsor
Clinvest
Individual
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
2
States / cities
Oviedo, Florida • Springfield, Missouri
Conditions
Migraine
Interventions
Fremanezumab, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
45
States / cities
Little Rock, Arkansas • Banning, California • Loma Linda, California + 37 more
Conditions
Migraine, Episodic Migraine, Phonophobia, Photophobia
Interventions
Rimegepant
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
441 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
19
States / cities
Phoenix, Arizona • Hawthorne, California • North Hollywood, California + 15 more
Conditions
Migraine
Interventions
Lu AG09222, Placebo
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 65 Years
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
3
States / cities
Oceanside, California • Sherman Oaks, California • Miami, Florida
Conditions
Migraine
Interventions
Sumatriptan/Naproxen Sodium, Naproxen Sodium
Drug
Lead sponsor
Cady, Roger, M.D.
Individual
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Newport Beach, California • Springfield, Missouri
Conditions
Episodic Migraine
Interventions
Xeomin, Placebo
Drug
Lead sponsor
Merz Therapeutics GmbH
Industry
Eligibility
18 Years and older
Enrollment
990 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
47
States / cities
Chandler, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 43 more
Conditions
Migraine Headache
Interventions
Kiko exercises-combines breathing and movement
Behavioral
Lead sponsor
Regional Clinical Research
Other
Eligibility
18 Years to 70 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Endwell, New York
Conditions
Migraine, Episodic Migraine, Chronic Migraine, Headache
Interventions
CGRP antibody or gepant
Drug
Lead sponsor
Hospital Universitari Vall d'Hebron Research Institute
Other
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Miami, Florida
Conditions
Migraine
Interventions
divalproex sodium
Drug
Lead sponsor
Abbott
Industry
Eligibility
12 Years to 17 Years
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
North Chicago, Illinois
Terminated Phase 3 Interventional Results available

The Childhood and Adolescent Migraine Prevention Study

NCT01581281
Conditions
Migraine, Migraine Disorders, Headache
Interventions
Amitriptyline, Topiramate, Placebo
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
8 Years to 17 Years
Enrollment
488 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
35
States / cities
Phoenix, Arizona • San Francisco, California • Stanford, California + 32 more
Conditions
Migraine, Traumatic Brain Injury, Anomalous Health Incidents
Interventions
Xeomin (incobotulinumtoxinA)
Drug
Lead sponsor
Uniformed Services University of the Health Sciences
Federal
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Episodic Migraine
Interventions
Atogepant
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 80 Years
Enrollment
685 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
113
States / cities
Chandler, Arizona • Phoenix, Arizona • Tucson, Arizona + 91 more
Conditions
Treatment for Prevention of Chronic Migraine
Interventions
Erenumab, Placebo
Biological · Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
667 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
34
States / cities
La Jolla, California • Newport Beach, California • San Francisco, California + 30 more
Conditions
Migraine Prophylaxis
Interventions
Fremanezumab, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
838 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
30
States / cities
Huntsville, Alabama • Long Beach, California • San Diego, California + 26 more
Conditions
Episodic Migraine
Interventions
Eptinezumab, Placebo
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
6 Years to 17 Years
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
15
States / cities
Stamford, Connecticut • Gulf Breeze, Florida • Hialeah, Florida + 12 more
Conditions
Migraine
Interventions
Erenumab, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
955 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
59
States / cities
Phoenix, Arizona • Anaheim, California • Encino, California + 55 more
Conditions
Migraine, Pain, Nausea, Vomiting, Aura
Interventions
Arm 1: CL-H1T, Arm 2: CL-H1T, Arm 3: Sumatriptan Succinate 100 mg capsule, Arm 4: Promethazine HCl 18.75 mg, Arm 5: Promethazine HCl 37.5 mg, Placebo
Drug · Other
Lead sponsor
Charleston Laboratories, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
475 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
3
States / cities
New Port Richey, Florida • North Miami Beach, Florida • Greer, South Carolina
Conditions
Treatment for Prevention of Chronic Migraine
Interventions
Erenumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 66 Years
Enrollment
609 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
29
States / cities
Newport Beach, California • Palo Alto, California • Santa Monica, California + 25 more